Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment.

Abstract

BACKGROUND Tuberculosis (TB) risk and mortality increase in the 6 months after highly active antiretroviral therapy (HAART) initiation. This short-term risk may be a consequence of HAART initiation and immune reconstitution. Alternatively, it may be due to confounding by low CD4 counts and high HIV viral loads (VLs). We assessed the TB risk before and after… (More)
DOI: 10.1097/QAI.0000000000001018

Topics

Cite this paper

@article{Pettit2016TimingOA, title={Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment.}, author={April C Pettit and Adell Mendes and Cathy Jenkins and Sonia Napravnik and Aimee Freeman and Bryan E Shepherd and David S Dowdy and John Gill and Anita Rochelle Rachlis and Richard Moore and Timothy R. Sterling}, journal={Journal of acquired immune deficiency syndromes}, year={2016}, volume={72 5}, pages={572-8} }